Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab in Early Stage Non-small Cell Lung Cancer
NCT03030131Phase 2Terminated
- Sponsor
- IFCT
- Start
- Jan 2017
- Primary completion
- Aug 2019
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by IFCT. Started Jan 2017; status: terminated.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03030131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03030131.